FDA/CDC

FDA advisory committee recommends volanesorsen for rare triglyceride disorder


 

REPORTING FROM an fda advisory committee meeting

The FDA is expected to decide on the application by August 30. The FDA usually follows the recommendations of its advisory panels, which are not binding.


ilacy@mdedge.com

Pages

Recommended Reading

VIDEO: Meta-analysis: Mortality, safety data may favor SGLT2 inhibitors in T2DM
MDedge Internal Medicine
Clopidogrel flunks platelet reactivity control test in TAVI
MDedge Internal Medicine
Targeting obesity could slow brain aging in psychosis
MDedge Internal Medicine
VIDEO: ZIP code, not gene code – Social factors shape patients’ health
MDedge Internal Medicine
Statin-associated muscle symptoms? Rechallenge!
MDedge Internal Medicine
CVD risk high in individuals who once had metabolically healthy obesity
MDedge Internal Medicine
Sucralose sparks appetite in obese, not lean, individuals
MDedge Internal Medicine
MI before age 50? Think familial hypercholesterolemia, substance abuse
MDedge Internal Medicine
Metabolic syndrome scoring system predicts CVD in type 2 diabetes
MDedge Internal Medicine
Obesity and weight loss both linked to RA disability
MDedge Internal Medicine